In Vitro Synergy and In Vivo Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis

Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00310-19. doi: 10.1128/AAC.00310-19. Print 2019 Oct.

Abstract

The mortality rate associated with Vibrio vulnificus sepsis remains high. An in vitro time-kill assay revealed synergism between tigecycline and ciprofloxacin. The survival rate was significantly higher in mice treated with tigecycline plus ciprofloxacin than in mice treated with cefotaxime plus minocycline. Thus, combination treatment with tigecycline-ciprofloxacin may be an effective novel antibiotic regimen for V. vulnificus sepsis.

Keywords: V. vulnificus; sepsis; tigecycline.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Cefotaxime / pharmacology
  • Ciprofloxacin / pharmacology*
  • Colony Count, Microbial
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination
  • Female
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Minocycline / pharmacology
  • Sepsis / drug therapy*
  • Sepsis / microbiology
  • Sepsis / mortality
  • Sepsis / pathology
  • Survival Analysis
  • Tigecycline / pharmacology*
  • Vibrio Infections / drug therapy*
  • Vibrio Infections / microbiology
  • Vibrio Infections / mortality
  • Vibrio Infections / pathology
  • Vibrio vulnificus / drug effects*
  • Vibrio vulnificus / growth & development

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Tigecycline
  • Minocycline
  • Cefotaxime